Published: November 12, 2026
Negotiation pathways
We identified 2 options to expand the early negotiation process (ENP) beyond its current Project Orbis scope to support timely public coverage for a broader range of new drugs. We asked for your feedback and learned from those insights.
A summary of what we heard during the public consultation is now available.
In our consultation, we heard strong support to expand ENP eligibility through the Health Canada Priority Review option. This was the clear preference of 91% of respondents. They noted its clear and transparent eligibility framework, application to a broader range of drugs, and more mature evidence base as good reasons to expand the ENP in this direction.
We're taking these insights into consideration as we continue to shape the ENP expansion, with a launch in the coming months.
We're grateful to everyone who took the time to provide input through our online survey and by participating in a webinar. Thank you for your contribution to inform the ENP expansion.